Cited by 1,280Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 322 of the 322 references it cites were found in a registry or an index.

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Open access

Lindeman, Neal I., Cagle, Philip T., Beasley, Mary Beth, Chitale, Dhananjay Arun, Dacic, Sanja, Giaccone, Giuseppe, Jenkins, Robert Brian, Kwiatkowski, David J., Saldivar, Juan-Sebastian, Squire, Jeremy, Thunnissen, Erik, Ladanyi, Marc·2013·Journal of Thoracic Oncology

DOI 10.1097/jto.0b013e318290868fPMC PMC4159960

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE: To establish evidence-based recommendations for the molecular analysis of lung cancers that are that are required to guide EGFR- and ALK-directed therapies, addressing which patients and samples should be tested, and when and how testing should be performed. PARTICIPANTS: Three cochairs without conflicts of interest were selected, one from each of the 3 sponsoring professional societies: College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Writing and advisory panels were constituted from additional experts from these societies. EVIDENCE: Three unbiased literature searches of electronic databases were performed to capture articles published published from January 2004 through February 2012, yielding 1533 articles whose abstracts were screened to identify 521 pertinent articles that were then reviewed in detail for their relevance to the recommendations. Evidence was formally graded for each recommendation. CONSENSUS PROCESS: Initial recommendations were formulated by the cochairs and panel members at a public meeting. Each guideline section was assigned to at least 2 panelists. Drafts were circulated to the writing panel (version 1), advisory panel (version 2), and the public (version 3) before submission (version 4). CONCLUSIONS: The 37 guideline items address 14 subjects, including 15 recommendations (evidence grade A/B). The major recommendations are to use testing for EGFR mutations and ALK fusions to guide patient selection for therapy with an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitor, respectively, in all patients with advanced-stage adenocarcinoma, regardless of sex, race, smoking history, or other clinical risk factors, and to prioritize EGFR and ALK testing over other molecular predictive tests. As scientific discoveries and clinical practice outpace the completion of randomized clinical trials, evidence-based guidelines developed by expert practitioners are vital for communicating emerging clinical standards. Already, new treatments targeting genetic alterations in other, less common driver oncogenes are being evaluated in lung cancer, and testing for these may be addressed in future versions of these guidelines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e318290868f

Cites

322 of 322 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citation
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 4×
“001).(7) Subsequently, 5 additional randomized controlled trials confirmed this association between activating EGFR mutations and objective response to gefitinib and/or erlotinib therapy (Table 2).”
Influential
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Schil, P. E. V., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,834
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Côté, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,424
Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews
Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., Porter, A. C., Tugwell, P., Moher, D., & Bouter, L. M. (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-10 · Cited by 4,374
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“Initial reports found this mutation in approximately 50%of tumors at the time of treatment failure.(137,168) However, because T790M is often not present in every tumor cell, conventional Sanger sequencing, even with microdissection, is considered insufficient for this testing.”
Background
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
Newton, C. R., Graham, A., Heptinstall, L., Powell, S. J., Summers, C. W., Kalsheker, N. A., Smith, J. C., & Markham, A. F. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.7.2503 · Cited by 2,483
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Inhibition and facilitation of nucleic acid amplification
Wilson, I. G. (1997) · Applied and Environmental Microbiology · doi:10.1128/aem.63.10.3741-3751.1997 · Cited by 2,298
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Self-citation
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Côté, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A. S., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,813
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Self-citation
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M. A., Solomon, B., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,337
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids
Srinivasan, M., Sedmak, D. D., & Jewell, S. D. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64472-0 · Cited by 1,320
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
Bamford, S., Dawson, E., Forbes, S. A., Clements, J., Pettett, R., Doǧan, A., Flanagan, A. M., Teague, J. W., Futreal, P. A., Stratton, M. R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601894 · Cited by 1,248
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,186
Formaldehyde fixation.
Fox, C. H., JOHNSON, F. B., Whiting, J., & Pp, R. (1985) · Journal of Histochemistry & Cytochemistry · doi:10.1177/33.8.3894502 · Cited by 1,098
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2906 · Cited by 1,083
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
Koivunen, J. P., Mermel, C. H., Zejnullahu, K., Murphy, C., Lifshits, E., Tisch, A. H., Choi, H. G., Kim, J., Chiang, D. Y., Thomas, R. K., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0168 · Cited by 1,001
Self-citation
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
Self-citation
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Shaw, A. T., Yeap, B. Y., Solomon, B., Riely, G. J., Gainor, J. F., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 897
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom, T., Brennan, K. W., et al. (2012) · Nature Medicine · doi:10.1038/nm.2673 · Cited by 869
KIF5B-RET fusions in lung adenocarcinoma
Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2644 · Cited by 834
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A. C., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 823
Self-citation
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Jackman, D., Pao, W., Riely, G. J., Engelman, J. A., Kris, M. G., Jänne, P. A., Lynch, T., Johnson, B. E., & Miller, V. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7049 · Cited by 793
EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment
Marchetti, A., Martella, C., Felicioni, L., Barassi, F., Salvatore, S., Chella, A., Camplese, P., Iarussi, T., Mucilli, F., Mezzetti, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.043 · Cited by 780
Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
Han, S., Kim, T., Hwang, P. G., Jeong, S., Kim, J., Choi, I. S., Oh, D., Kim, J. H., Kim, D., Chung, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.388 · Cited by 757
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Han, J.-Y., Park, K., Kim, S.-W., Lee, D. H., Kim, H. Y., Kim, H. T., Ahn, M. J., Yun, T., Ahn, J. S., Suh, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.8456 · Cited by 736
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
Riely, G. J., Pao, W. J., Ceppa, D. P., Li, A. R., Rizvi, N. A., Venkatraman, E. S., Zakowski, M. F., Kris, M. G., Ladanyi, M., & Miller, V. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1846 · Cited by 730
Self-citation
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
Miller, V. A., Kris, M. G., Shah, N., Patel, J. D., Azzoli, C. G., Gomez, J. E., Krug, L. M., Pao, W. J., Rizvi, N. A., Pizzo, B., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.158 · Cited by 728
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 721
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710
Self-citation
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Engelman, J. A., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 706
Detection of PCR products using self-probing amplicons and fluorescence
Whitcombe, D. M., Theaker, J., Guy, S. P., Brown, T., & Little, S. (1999) · Nature Biotechnology · doi:10.1038/11751 · Cited by 697
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
Takano, T., Ohe, Y., Sakamoto, H., Tsuta, K., Matsuno, Y., Tateishi, U., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.0793 · Cited by 696
Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population
Rodig, S. J., Mino-Kenudson, M. A., Đačić, S., Yeap, B. Y., Shaw, A. T., Barletta, J. A., Stubbs, H., Law, K., Lindeman, N. I., Mark, E. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0802 · Cited by 677
Self-citation
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
Zhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8924 · Cited by 661
Self-citation
Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers
Dogan, S., Shen, R., Ang, D. C., Johnson, M. L., D'Angelo, S. P., Paik, P. K., Brzostowski, E. B., Riely, G. J., Kris, M. G., Zakowski, M. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3265 · Cited by 639
Self-citation
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Roychowdhury, S., Iyer, M. K., Robinson, D. R., Lonigro, R. J., Wu, Y.-M., Cao, X., Sundaram, S. K., Sam, L. T., Balbin, O. A., Quist, M. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003161 · Cited by 638
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Sasaki, T., Koivunen, J. P., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C. S., Marcoux, J. P., Du, J., Okuda, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1340 · Cited by 608
Self-citation
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., Sgroi, D. C., Muir, B., Riemenschneider, M. J., Iacona, R. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7078 · Cited by 598
Self-citation
KRASMutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
Massarelli, E., Varella‐Garcia, M., Tang, X., Xavier, A. C., Ozburn, N. C., Liu, D. D., Bekele, B. N., Herbst, R. S., & Wistuba, I. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3043 · Cited by 594
Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0646 · Cited by 578
Self-citation
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574
Self-citation
Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study
Hirsch, F. R., Varella‐Garcia, M., McCoy, J., West, H., Xavier, A. C., Gumerlock, P. H., Bunn, P. A., Franklin, W. A., Crowley, J. J., & Gandara, D. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.2823 · Cited by 574
High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan
Huang, S.-F. K., Liu, H.-P., Li, L.-H., Ku, Y.-C., Fu, Y.-N., Tsai, H., Chen, Y.-T., Lin, Y., Chang, W.-C., Kuo, H.-P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1245 · Cited by 545
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K. E., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M. E., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 529
Self-citation
A High Frequency of Sequence Alterations Is Due to Formalin Fixation of Archival Specimens
Williams, C., Pontén, F., Moberg, C., Söderkvist, P., Uhlén, M., Pontén, J., Sitbon, G., & Lundeberg, J. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65461-2 · Cited by 514
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., Watanabe, H., Saijo, Y., & Nukiwa, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4692 · Cited by 509
Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas
Arcila, M. E., Chaft, J. E., Nafa, K., Roy-Chowdhuri, S., Lau, C., Zaidinski, M., Paik, P. K., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0912 · Cited by 505
Self-citation
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy
Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Yamazaki, K., Saijo, Y., Gemma, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7658 · Cited by 505
Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
Takeuchi, K., Choi, Y. L., Soda, M., Inamura, K., Togashi, Y., Hatano, S., Enomoto, M., Takada, S., Yamashita, Y., Satoh, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1018 · Cited by 505
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial
Douillard, J.-Y., Shepherd, F. A., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Liao, M.-L., Bischoff, H., Reck, M., Sellers, M. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3030 · Cited by 492
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Keedy, V. L., Temin, S., Somerfield, M. R., Beasley, M. B., Johnson, D. H., McShane, L. M., Milton, D. T., Strawn, J. R., Wakelee, H. A., & Giaccone, G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8923 · Cited by 490
Self-citation
The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers
Tokumo, M., Toyooka, S., Kiura, K., Shigematsu, H., Tomii, K., Aoe, M., Ichimura, K., Tsuda, T., Yano, M., Tsukuda, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1167.11.3 · Cited by 489
Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations
Tsiatis, A. C., Norris-Kirby, A., Rich, R. G., Hafez, M. J., Gocke, C. D., Eshleman, J. R., & Murphy, K. M. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090188 · Cited by 488
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencingPreprint
Ju, Y. S., Lee, W., Shin, J.-Y., Lee, S., Bleazard, T., Won, J., Kim, Y. T., Kim, J., Kang, J. H., & Seo, J. (2011) · Genome Research · doi:10.1101/gr.133645.111 · Cited by 486
EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473
Self-citation
EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
Inamura, K., Takeuchi, K., Togashi, Y., Nomura, K., Ninomiya, H., Okui, M., Satoh, Y., Okumura, S., Nakagawa, K., Soda, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815e8b60 · Cited by 466
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
Engelman, J. A., Mukohara, T., Zejnullahu, K., Lifshits, E., Borras, A. M., Gale, C.-M., Naumov, G. N., Yeap, B. Y., Jarrell, E., Sun, J., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28656 · Cited by 457
Presence ofEpidermal Growth Factor ReceptorGene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer
Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., Suehisa, H., Ouchida, M., Aoe, K., Aoe, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1951 · Cited by 450
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset
Inamura, K., Takeuchi, K., Togashi, Y., Hatano, S., Ninomiya, H., Motoi, N., Mun, M., Sakao, Y., Okumura, S., Nakagawa, K., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.2 · Cited by 442
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
Nguyen, K.-S. H., Kobayashi, S., & Costa, D. B. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.039 · Cited by 437
Extending an evidence hierarchy to include topics other than treatment: revising the Australian 'levels of evidence'
Merlin, T., Weston, A., & Tooher, R. (2009) · BMC Medical Research Methodology · doi:10.1186/1471-2288-9-34 · Cited by 435
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK -Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
Mino-Kenudson, M. A., Chirieac, L. R., Law, K., Hornick, J. L., Lindeman, N. I., Mark, E. J., Cohen, D., Johnson, B. E., Janne, P. A., Iafrate, A. J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2845 · Cited by 424
Self-citation
Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features
Tam, I. Y. S., Chung, L.-P., Suen, W., Wang, E., Wong, M. C. M., Ho, K. K., Lam, W. K., Chiu, S. W., Girard, L., Minna, J. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1981 · Cited by 400
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
Jackman, D. M., Miller, V. A., Cioffredi, L., Yeap, B. Y., Janne, P. A., Riely, G. J., Ruiz, M. I. G., Giaccone, G., Sequist, L. V. D., & Johnson, B. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0888 · Cited by 377
Self-citation
Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR / KRA S and Presence of PIK3CA / AKT1 Mutations
Rekhtman, N., Paik, P. K., Arcila, M. E., Tafe, L. J., Oxnard, G. R., Moreira, A. L., Travis, W. D., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2109 · Cited by 361
Self-citation
Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
Camidge, D. R., Kono, S. A., Flacco, A., Tan, A. C., Doebele, R. C., Zhou, Q. H., Crinò, L., Franklin, W. A., & Varella‐Garcia, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0851 · Cited by 341
Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
Rekhtman, N., Ang, D. C., Sima, C. S., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.92 · Cited by 340
Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
Sun, Y., Ren, Y., Fang, Z., Li, C., Fang, R., Gao, B., Han, X., Tian, W., Pao, W. J., Chen, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6038 · Cited by 337
The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
Sasaki, T., Okuda, K., Zheng, W., Butrynski, J. E., Capelletti, M., Wang, L., Gray, N. S., Wilner, K. D., Christensen, J. G., Demetri, G. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2956 · Cited by 333
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas
Tarón, M., Ichinose, Y., Rosell, R., Mok, T. S. K., Massutí, B., Zamora, L., Mate, J. L., Manegold, C., Ono, M., Queralt, C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2618 · Cited by 332
Clinicopathologic Features of Non-Small-Cell Lung Cancer with EML4–ALK Fusion Gene
Takahashi, T., Sonobe, M., Kobayashi, M., Yoshizawa, A., Menju, T., Nakayama, E., Mino, N., Iwakiri, S., Sato, K., Miyahara, R., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0808-7 · Cited by 326
Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer
Kimura, H., Kasahara, K., Kawaishi, M., Kunitoh, H., Tamura, T., Holloway, B. R., & Nishio, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2324 · Cited by 321
EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
Horn, L., & Pao, W. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6661 · Cited by 317
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
Porta, R., Sánchez-Torres, J. M., Paz-Ares, L., Massutí, B., Reguart, N., Mayo, C., Lianes, P., Queralt, C., Guillem, V., Salinas, P., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00195609 · Cited by 316
Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer
Chou, T., Chiu, C., Li, L., Hsiao, C.-Y., Tzen, C., Chang, K.-T., Chen, Y., Perng, R.-P., Tsai, S., & Tsai, C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1981 · Cited by 315
Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer
Jackman, D. M., Yeap, B. Y., Lindeman, N. I., Fidias, P., Rabin, M. S., Temel, J. S., Skarin, A. T., Meyerson, M. M., Tisch, A. H., Borras, A. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.5754 · Cited by 304
Self-citation
Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting
Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 302
Self-citation
Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib
Miller, V. A., Riely, G. J., Zakowski, M. F., Li, A. R., Patel, J. D., Heelan, R. T., Kris, M. G., Sandler, A. B., Carbone, D. P., Tsao, A. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0062 · Cited by 298
Self-citation
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Zhang, X., Zhang, S., Yang, X., Yang, J., Zhou, Q. H., Yin, L., An, S., Lin, J., Chen, S., Xie, Z., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-188 · Cited by 296
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer
Krypuy, M., Newnham, G. M., Thomas, D. M., Conron, M., & Dobrovic, A. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-295 · Cited by 288
Evaluation of Non-Formalin Tissue Fixation for Molecular Profiling Studies
Gillespie, J. W., Best, C. J. M., Bichsel, V. E., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64864-x · Cited by 285
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer
Brugger, W., Triller, N., Błasińska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G. M., Mazières, J., Whittom, R., Ward, C., Mayne, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8162 · Cited by 284
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
Pirker, R., Herth, F. J. F., Kerr, K. M., Filipits, M., Tarón, M., Gandara, D. R., Hirsch, F. R., Grunenwald, D. H., Popper, H., Smit, E. F., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f1c8de · Cited by 283
Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization
Paik, J. H., Choe, G., Kim, H., Choe, J., Lee, H. J., Lee, C., Lee, J. S., Jheon, S., & Chung, J.-H. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820b82e8 · Cited by 277
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
Asahina, H., Yamazaki, K., Kinoshita, I., Sukoh, N., Harada, M., Yokouchi, H., Ishida, T., Ogura, S., Kojima, T., Okamoto, Y., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603393 · Cited by 276
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
Grève, J. D., Teugels, E., Geers, C., Decoster, L., Galdermans, D., Mey, J. D., Everaert, H., Umelo, I. A., Veld, P. I. '., & Schallier, D. C. C. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.01.008 · Cited by 272
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
Hirsch, F. R., Varella‐Garcia, M., Cappuzzo, F., McCoy, J., Bemis, L., Xavier, A. C., Dziadziuszko, R., Gumerlock, P. H., Chansky, K., West, H., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm003 · Cited by 270
Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma
Marks, J. L., Broderick, S., Zhou, Q. C., Chitale, D. A., Li, A. R., Zakowski, M. F., Kris, M. G., Rusch, V. W., Azzoli, C. G., Seshan, V., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318160c607 · Cited by 268
Self-citation
KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only
Togashi, Y., Soda, M., Sakata, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031323 · Cited by 268
Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer
Khambata‐Ford, S., Harbison, C. T., Hart, L. L., Awad, M., Xu, L., Horak, C. E., Dakhil, S. R., Hermann, R. C., Lynch, T. J., & Weber, M. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2890 · Cited by 265
Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma: IHC Score Algorithm for FISH
Yi, E. S., Boland, J. M., Maleszewski, J. J., Roden, A. C., Oliveira, A. M., Aubry, M.-C., Erickson‐Johnson, M. R., Caron, B. L., Li, Y., Tang, H. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318209edb9 · Cited by 260
EGFR Mutations in Small-Cell Lung Cancers in Patients Who Have Never Smoked
Zakowski, M. F., Ladanyi, M., & Kris, M. G. (2006) · New England Journal of Medicine · doi:10.1056/nejmc053610 · Cited by 254
Self-citation
EML4-ALK Fusion Lung Cancer: A Rare Acquired Event
Perner, S., Wagner, P. L., Demichelis, F., Mehra, R., Lafargue, C. J., Moss, B. J., Arbogast, S., Soltermann, A., Weder, W., Giordano, T. J., et al. (2008) · Neoplasia · doi:10.1593/neo.07878 · Cited by 249
Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas
Pan, Q., Pao, W. J., & Ladanyi, M. (2005) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60569-7 · Cited by 245
Self-citation
Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
Yang, C.-H., Yu, C., Shih, J., Chang, Y., Hu, F., Tsai, M.-C., Chen, K., Lin, Z., Huang, C.-J., Shun, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6695 · Cited by 238
Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing
Rekhtman, N., Brandt, S. M., Sigel, C., Friedlander, M. A., Riely, G. J., Travis, W. D., Zakowski, M. F., & Moreira, A. L. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820517a3 · Cited by 236
Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer
Yu, J. Q., Kane, S. E., Wu, J., Benedettini, E., Li, D., Reeves, C., Innocenti, G., Wetzel, R., Crosby, K., Becker, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2739 · Cited by 235
Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
Soh, J., Okumura, N., Lockwood, W. W., Yamamoto, H., Shigematsu, H., Zhang, W., Chari, R., Shames, D. S., Tang, X., MacAulay, C. E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007464 · Cited by 234
Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer
Kuang, Y., Rogers, A. M., Yeap, B. Y., Wang, L., Makrigiorgos, M. G., Vetrand, K., Thiede, S., Distel, R. J., & Janne, P. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2592 · Cited by 232
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
Cortés-Funes, H., Gómez, C. G., Rosell, R., Valero, P. M., Girón, C. G., Velasco, A., Izquierdo, Á., Díz, P., Camps, C., Castellanos, D., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi221 · Cited by 229
EGFR and KRAS mutations in lung carcinoma
Billah, S., Stewart, J., Staerkel, G., Chen, S., Gong, Y., & Guo, M. (2011) · Cancer Cytopathology · doi:10.1002/cncy.20151 · Cited by 226
Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma
Yatabe, Y., Matsuo, K., & Mitsudomi, T. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.3906 · Cited by 223
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
Jänne, P. A., Borras, A. M., Kuang, Y., Rogers, A. M., Joshi, V. A., Liyanage, H., Lindeman, N., Lee, J. C., Halmos, B., Maher, E. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2047 · Cited by 214
Self-citation
EGFR Mutations in Lung Adenocarcinomas
Li, A. R., Chitale, D. A., Riely, G. J., Pao, W. J., Miller, V. A., Zakowski, M. F., Rusch, V. W., Kris, M. G., & Ladanyi, M. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070178 · Cited by 214
Self-citation
Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial
Cappuzzo, F., Ligorio, C., Janne, P. A., Toschi, L., Rossi, E., Trisolini, R., Paioli, D., Tisch, A. H., Magrini, E., Finocchiaro, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4300 · Cited by 210
Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas
Ceppa, D. P., Kris, M. G., Riely, G. J., Sarkaria, I. S., McDonough, T. L., Chuai, S., Venkatraman, E. S., Miller, V. A., Ladanyi, M., Pao, W. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3224 · Cited by 210
Self-citation
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
O'Byrne, K. J., Gatzemeier, U., Bondarenko, I., Barrios, C. H., Eschbach, C., Martens, U. M., Hotko, Y., Kortsik, C., Paz-Ares, L. G., Pereira, J. R., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70189-9 · Cited by 209
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies
Do, H., Krypuy, M., Mitchell, P. L. R., Fox, S. B., & Dobrovic, A. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-142 · Cited by 206
Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR
Brevet, M., Arcila, M. E., & Ladanyi, M. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090140 · Cited by 205
Self-citation
Assessment of Epidermal Growth Factor Receptor Mutation by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
Nakajima, T., Yasufuku, K., Suzuki, M., Hiroshima, K., Kubo, R., Mohammed, S., Miyagi, Y., Matsukuma, S., Sekine, Y., & Fujisawa, T. (2007) · CHEST Journal · doi:10.1378/chest.07-0095 · Cited by 198
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Heuckmann, J. M., Hölzel, M., Sos, M. L., Heynck, S., Balke‐Want, H., Koker, M., Peifer, M., Weiss, J. M., Lovly, C. M., Grütter, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1648 · Cited by 195
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer
Tatematsu, A., Shimizu, J., Murakami, Y., Horio, Y., Nakamura, S., Hida, T., Mitsudomi, T., & Yatabe, Y. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0332 · Cited by 191
A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer
Yatabe, Y., Hida, T., Horio, Y., Kosaka, T., Takahashi, T., & Mitsudomi, T. (2006) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.050104 · Cited by 186
Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib
D’Angelo, S. P., Janjigian, Y. Y., Ahye, N., Riely, G. J., Chaft, J. E., Sima, C. S., Shen, R., Zheng, J., Dycoco, J., Kris, M. G., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826bb7b2 · Cited by 184
Self-citation
Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR
van Eijk, R., Licht, J., Schrumpf, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017791 · Cited by 181
Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions
Suehara, Y., Arcila, M. E., Wang, L., Hasanovic, A., Ang, D. C., Ito, T., Kimura, Y., Drilon, A. E. D. C., Guha, U., Rusch, V. W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0838 · Cited by 181
Self-citation
Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
Ludovini, V., Bianconi, F., Pistola, L., Chiari, R., Minotti, V., Colella, R., Giuffrida, D., Tofanetti, F. R., Siggillino, A., Flacco, A., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820a3a6b · Cited by 180
A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.
Su, Z., Dias-Santagata, D., Duke, M., Hutchinson, K., Lin, Y.-L., Borger, D. R., Chung, C. H., Massion, P. P., Vnencak-Jones, C. L., Iafrate, A. J., et al. (2011) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.11.010 · Cited by 176
Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non–small cell lung carcinomas
Boland, J. M., Erdogan, S., Vasmatzis, G., Yang, P., Tillmans, L. S., Johnson, M. R., Wang, X., Peterson, L. M., Halling, K. C., Oliveira, A. M., et al. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.01.012 · Cited by 171
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
Yang, J. C., Schüler, M., Yamamoto, N., O'Byrne, K. J., Hirsh, V., Mok, T. S. K., Geater, S. L., Orlov, S., Tsai, C., Boyer, M. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.lba7500 · Cited by 171
Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer
Kim, K., Jeong, J.-Y., Kim, Y., Na, K.-J., Kim, Y., Ahn, S., Baek, S.-M., Park, C.-S., Park, C.-M., Kim, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2081 · Cited by 168
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
Sutani, A., Nagai, Y., Udagawa, K., Uchida, Y., Koyama, N., Murayama, Y., Tanaka, T., Miyazawa, H., Nagata, M., Kanazawa, M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603466 · Cited by 167
EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas
Shinmura, K., Kageyama, S., Tao, H., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.12.013 · Cited by 164
Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma
Sonobe, M., Manabe, T., Wada, H., & Tanaka, F. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602707 · Cited by 162
Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization with Correlation of ALK Protein Expression
Kim, H., Yoo, S.-B., Choe, J., Paik, J. H., Xu, X., Nitta, H., Zhang, W., Grogan, T. M., Lee, C., Jheon, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821cfc73 · Cited by 162
Response to Treatment and Survival of Patients with Non-Small Cell Lung Cancer Undergoing SomaticEGFRMutation Testing
Sequist, L. V. D., Joshi, V. A., Janne, P. A., Muzikansky, A., Fidias, P. M., Meyerson, M. M., Haber, D. A., Kucherlapati, R., Johnson, B. E., & Lynch, T. J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-90 · Cited by 161
EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer
Smouse, J. H., Cibas, E. S., Janne, P. A., Joshi, V. A., Zou, K. H., & Lindeman, N. I. (2009) · Cancer Cytopathology · doi:10.1002/cncy.20011 · Cited by 160
Self-citation
Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer
Salido, M., Pijuán, L., Martinez-Aviles, L. M., Galván, A. B., Cañadas, I., Rovira, A., Zanui, M., Martínez, A., Longarón, R., Solé, F. G., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fb7cd6 · Cited by 159
Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?
Antoniu, S. A. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.550880 · Cited by 157
Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer
Dziadziuszko, R., Wynes, M. W., Singh, S., Asuncion, B. R., Ranger‐Moore, J., Konopa, K., Rzyman, W., Szostakiewicz, B., Jassem, J., & Hirsch, F. R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318240ca0d · Cited by 156
Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer
Ogino, S., Meyerhardt, J. A., Cantor, M., Brahmandam, M., Clark, J. W., Namgyal, C., Kawasaki, T., Kinsella, K., Michelini, A. L., Enzinger, P. C., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0738 · Cited by 156
Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database
Murray, S. J., Dahabreh, I. J., Linardou, H., Manoloukos, M., Bafaloukos, D. I., & Kosmidis, P. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31818071f3 · Cited by 154
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer
Paik, J. H., Choi, C., Kim, H., Jang, S. J., Choe, G., Kim, D. K., Kim, H. J., Yoon, H.-I., Lee, C., Jheon, S., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.11.008 · Cited by 154
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay
Endo, K., Konishi, A., Sasaki, H., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.08.009 · Cited by 152
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149
Self-citation
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
van Zandwijk, N., Mathy, A., Boerrigter, L., Ruijter, H. J., Tielen, I. H. G., de Jong, D., Baas, P., Burgers, S. A., & Nederlof, P. M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl323 · Cited by 147
Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
Park, S. E., Tisch, A. H., Cho, E. Y., Shim, Y. M., Kim, J., Kim, H. S., Lee, J., Park, Y. H., Ahn, J. S., Park, K., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a94af4 · Cited by 145
Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status
Onitsuka, T., Uramoto, H., Nose, N., Takenoyama, M., Hanagiri, T., Sugio, K., & Yasumoto, K. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.022 · Cited by 142
FORM: An Australian method for formulating and grading recommendations in evidence-based clinical guidelines
Hillier, S., Grimmer, K. A., Merlin, T., et al. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-23 · Cited by 139
Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans
Reinersman, J. M., Johnson, M. L., Riely, G. J., Chitale, D. A., Nicastri, A. D., Soff, G. A., Schwartz, A. G., Sima, C. S., Ayalew, G. D., Lau, C., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181fb4fe2 · Cited by 139
Self-citation
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking
Sugio, K., Uramoto, H., Ono, K., Oyama, T., Hanagiri, T., Sugaya, M., Ichiki, Y., So, T., Nakata, S., Morita, M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603040 · Cited by 138
Recommendations for Validating Estrogen and Progesterone Receptor Immunohistochemistry Assays
Fitzgibbons, P. L., Murphy, D. A., Hammond, M. E. H., et al. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.6.930 · Cited by 131
Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping
Oxnard, G. R., Miller, V. A., Robson, M. E., Azzoli, C. G., Pao, W. J., Ladanyi, M., & Arcila, M. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318250ed9d · Cited by 130
Self-citation
Clinicopathologic Significance of the Mutations of theEpidermal Growth Factor ReceptorGene in Patients with Non–Small Cell Lung Cancer
Tomizawa, Y., Iijima, H., Sunaga, N., Sato, K., Takise, A., Otani, Y., Tanaka, S., Suga, T., Saito, R., Ishizuka, T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0441 · Cited by 129
Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer
Tsao, A. S., Tang, X., Sabloff, B. S., Xiao, L., Shigematsu, H., Roth, J. A., Spitz, M. R., Hong, W. K., Gazdar, A. F., & Wistuba, I. I. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31573-2 · Cited by 128
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy
Sunaga, N., Tomizawa, Y., Yanagitani, N., Iijima, H., Kaira, K., Shimizu, K., Tanaka, S., Suga, T., Hisada, T., Ishizuka, T., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.01.025 · Cited by 127
EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations
Tiseo, M., Gelsomino, F., Boggiani, D., Bortesi, B., Bartolotti, M., Bozzetti, C., Sammarelli, G., Thai, E., & Ardizzoni, A. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.11.014 · Cited by 125
Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers
Sholl, L. M., Yeap, B. Y., Iafrate, A. J., Tisch, A. H., Chou, Y.-P., Wu, M., Goan, Y., Su, L., Benedettini, E., Yu, J. Q., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2477 · Cited by 122
Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung
Kang, S. M., Kang, H. J., Shin, J. H., Kim, H., Shin, D. H., Kim, S. K., Kim, J.-H., Chung, K. S., Kim, S. K., & Chang, J. (2006) · Cancer · doi:10.1002/cncr.22413 · Cited by 122
The impact of epidermal growth factor receptor gene status on gefitinib‐treated Japanese patients with non‐small‐cell lung cancer
Ichihara, S., Toyooka, S., Fujiwara, Y., Hotta, K., Shigematsu, H., Tokumo, M., Soh, J., Asano, H., Ichimura, K., Aoe, K., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22513 · Cited by 119
Combining Highly Multiplexed PCR with Semiconductor-Based Sequencing for Rapid Cancer Genotyping
Beadling, C., Neff, T. L., Heinrich, M. C., Rhodes, K., Thornton, M., Leamon, J. H., Andersen, M., & Corless, C. L. (2012) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2012.09.003 · Cited by 119
Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing
Buttitta, F., Felicioni, L., Grammastro, M. D., Filice, G., Lorito, A. D., Malatesta, S., Viola, P., Centi, I., D’Antuono, T., Zappacosta, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1958 · Cited by 118
Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component
Yoshida, A., Tsuta, K., WATANABE, S.-I. I., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.09.013 · Cited by 118
Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations
Kato, Y., Peled, N., Wynes, M. W., Yoshida, K., Pardo, M., Mascaux, C., Ohira, T., Tsuboi, M., Matsubayashi, J., Nagao, T., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e9da60 · Cited by 118
Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation
Morinaga, R., Okamoto, I., Furuta, K., Kawano, Y., Sekijima, M., Dote, K., Satou, T., Nishio, K., Fukuoka, M., & Nakagawa, K. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.014 · Cited by 116
EGFR gene status in cytological samples of nonsmall cell lung carcinoma
Santos, G. D. C., Saieg, M. A., Geddie, W. R., & Leighl, N. B. (2011) · Cancer Cytopathology · doi:10.1002/cncy.20150 · Cited by 116
EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry
Sholl, L. M., Xiao, Y., Joshi, V. A., Yeap, B. Y., Cioffredi, L., Jackman, D. M., Lee, C., Janne, P. A., & Lindeman, N. I. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpst1cthzs3psz · Cited by 116
Self-citation
Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens
Querings, S., Altmüller, J., Ansén, S., Zander, T., Seidel, D., Gabler, F., Peifer, M., Markert, E., STEMSHORN, K. C., Timmermann, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019601 · Cited by 115
Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis
Kawahara, A., Yamamoto, C., Nakashima, K., Azuma, K., Hattori, S., Kashihara, M., Aizawa, H., Basaki, Y., Kuwano, M., Kage, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3239 · Cited by 114
Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer
Lara-Guerra, H., Waddell, T. K., Salvarrey, A. M., Joshua, A. M., Chung, C. T. ‐., Paul, N. S., Boerner, S. L., Sakurada, A., Ludkovski, O., Ma, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3370 · Cited by 113
Self-citation
Nomogram to predict the presence ofEGFRactivating mutation in lung adenocarcinoma
Girard, N., Sima, C. S., Jackman, D. M., Sequist, L. V. D., Chen, H., Yang, J. C., Ji, H., Waltman, B. A., Rosell, R., Tarón, M., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00010111 · Cited by 113
Self-citation
A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells
Molina‐Vila, M. Á., Bertrán-Alamillo, J., Reguart, N., Tarón, M., Castellà, E., Llatjós, M., Costa, C., Mayo, C., Pradas, A., Queralt, C., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318189f579 · Cited by 112
EGFR Mutation Status in Japanese Lung Cancer Patients: Genotyping Analysis Using LightCycler
Sasaki, H., Endo, K., Konishi, A., Takada, M., Kawahara, M., Iuchi, K., Matsumura, A., Okumura, M., Tanaka, H., Kawaguchi, T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1904 · Cited by 112
Screening for EGFR mutations in lung cancer, a report from India
Sahoo, R., Harini, V. V., Babu, V. C., Okaly, G. V. P., Rao, S., Nargund, A. R., Venkataswamy, E., Rao, R., & Kumar, B. S. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.01.004 · Cited by 111
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma
Rekhtman, N., Tafe, L. J., Chaft, J. E., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.195 · Cited by 111
EGFR mutation in gefitinib-responsive small-cell lung cancer
Okamoto, I., Araki, J., Suto, R., Shimada, M., Nakagawa, K., & Fukuoka, M. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj114 · Cited by 108
Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas
Đačić, S., Shuai, Y., Yousem, S. A., Ohori, P. N., & Nikiforova, M. N. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.154 · Cited by 108
Low Copy Number DNA Template Can Render Polymerase Chain Reaction Error Prone in a Sequence-Dependent Manner
Akbari, M., Hansen, M. D., Halgunset, J., Skorpen, F., & Krokan, H. E. (2005) · Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60006-2 · Cited by 107
Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer
Soh, J., Toyooka, S., Aoe, K., Asano, H., Ichihara, S., Katayama, H., Hiraki, A., Kiura, K., Aoe, M., Sano, Y., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22190 · Cited by 105
Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment
Han, S., Kim, H., Jeon, Y. K., Oh, D., Lee, S., Kim, D., Im, S., Chung, D. H., Heo, D. S., Bang, Y., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2007.11.014 · Cited by 103
Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non–Small Cell Lung Cancer Treated with Gefitinib
Takano, T., Ohe, Y., Tsuta, K., Fukui, T., Sakamoto, H., Yoshida, T., Tateishi, U., Nokihara, H., Yamamoto, N., Sekine, I., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0627 · Cited by 103
Preclinical validation of fluorescence in situ hybridization assays for clinical practice
Wiktor, A. E., Dyke, D. L. V., Stupca, P. J., et al. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000195645.00446.61 · Cited by 101

Research works printed but not linked: 1

Department of Health and Human Services, 1992, Clinical laboratory improvement amendments of 1988: final rule, Fed Regist, 57, 7001

Sorted by citations

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Self-citation
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Towards precision medicine
Ashley, E. A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.86 · Cited by 1,116
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
Kalemkerian, G. P., Narula, N., Kennedy, E. B., Biermann, W. A., Donington, J., Leighl, N. B., Lew, M., Pantelas, J., Ramalingam, S. S., Reck, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7293 · Cited by 492
Non–Small Cell Lung Cancer, Version 6.2015
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0071 · Cited by 478

See all 1,280

Authors: Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., Thunnissen, E., & Ladanyi, M.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Lindeman, Neal I.
Beasley, Mary Beth
Chitale, Dhananjay Arun
Giaccone, Giuseppe
Jenkins, Robert Brian
Kwiatkowski, David J.
Squire, Jeremy
Thunnissen, Erik
Ladanyi, Marc
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2013-07
Volume: 8
Issue: 7
Pages: 823-859
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1097/jto.0b013e318290868f
PMC: PMC4159960
OpenAlex: W1978236936
Cited by: 1,280
References: 322
Citations by year: 2026: 17 · 2025: 17 · 2024: 33 · 2023: 42 · 2022: 52 · 2021: 81 · 2020: 99 · 2019: 78 · 2018: 135 · 2017: 164 · 2016: 170 · 2015: 167 · 2014: 168 · 2013: 54
FWCI: 151.45
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 868 d)
Locations: Journal of Thoracic Oncology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
PubMed Central (acceptedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: National Cancer Institute (P01CA129243)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: lung cancer, EGFR mutation, ALK fusion, tyrosine kinase inhibitors, molecular testing, patient selection, predictive biomarkers, targeted therapy, molecular pathology
MeSH terms: Anaplastic Lymphoma Kinase, Systematic Reviews as Topic, Expert Testimony, Genetic Testing, Humans, International Agencies, Lung Neoplasms, Mutation, Societies, Medical, Biomarkers, Tumor, Gene Rearrangement, Patient Selection, Evidence-Based Medicine, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks